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The skeleton is a highly dynamic tissue whose structure relies on the balance
between bone deposition and resorption. This equilibrium, which depends on osteoblast
and osteoclast functions, is controlled by multiple factors that can be modulated
post-translationally. Some of the modulators are Mitogen-activated kinases (MAPKs),
whose role has been studied in vivo and in vitro. p38-MAPK modifies the transactivation
ability of some key transcription factors in chondrocytes, osteoblasts and osteoclasts,
which affects their differentiation and function. Several commercially available inhibitors
have helped to determine p38 action on these processes. Although it is frequently
mentioned in the literature, this chemical approach is not always as accurate as it should
be. Conditional knockouts are a useful genetic tool that could unravel the role of p38 in
shaping the skeleton. In this review, we will summarize the state of the art on p38 activity
during osteoblast differentiation and function, and emphasize the triggers of this MAPK.
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INTRODUCTION
Two decades ago, the Mitogen-activated kinases (MAPKs) were revealed as key players in
skeletal development and bone homeostasis that particularly affect osteoblast commitment and
differentiation. Of the three classic MAPKs, scientific evidence predominantly points to p38 and
ERK activities as determining and shaping the skeleton. Remarkably, there are hundreds of reports
of in vivo and in vitro studies that analyse the relevant role of p38 and ERK throughout the
osteoblastic commitment process, from a mesenchymal progenitor into a fully functional anabolic
bone cell. This field of study has been facilitated by the availability of specific inhibitors of MAPK
activity. However, these inhibitors may lead to dubious correlations between the specific causal
effect of MAPK inhibition and MAPKs’ role. There are several complete or cell-directed knockouts
that provide a broader view of the many effects that MAPKs have on bone differentiation. The
purpose of this review is to describe the precise role of p38-MAPK on osteoblast differentiation
and the several upstream events that can trigger its activation, in the interests of guiding anabolic
therapies for bone-related pathologies.
Bone and Its Constituents
The skeleton is a very dynamic, calcified organ whose structure is maintained by bone deposition
and resorption. During the last decade, new skeletal functions beyond those associated with
locomotion and organ protection have been discovered, including fertility, glucose and adipose
metabolism, phosphate renal clearance and maintenance of the hematopoietic niche (Karsenty
and Ferron, 2012). Structurally, bone tissue is composed of different cells and an extracellular
matrix (ECM). This matrix has two components: one organic and another inorganic. The latter
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is mainly formed by hydroxyapatite, which represents 99%
of the body’s calcium and 80% of the body’s phosphate.
The organic component is composed of collagen fibers,
glycosaminoglycans, proteoglycans and glycoproteins. Collagen
I is the most common protein in bone, accompanied by proteins
such as bone sialoprotein (IBSP) and osteonectin (SPARC).
Moreover, certain cytokines, such as TGF-β (transforming
growth factor-β) and BMP (bone morphogenetic protein),
remain bound to ECM fibers and can be freed during
resorption processes (Dallas et al., 2002; Gregory et al.,
2005).
Bone formation can be explained from two perspectives:
embryological origin, and ossification. Embryologically, facial
skeletal structures are derived from the ectoderm, while the axial
and appendicular skeletons emerge from the paraxial mesoderm
and the lateral mesoderm plate, respectively (Berendsen and
Olsen, 2015). Ossification can be defined as endochondral or
intramembranous. The latter mechanism occurs directly from
mesenchymal condensation, in which mesenchymal stem cells
(MSCs) differentiate into osteoblasts (Percival and Richtsmeier,
2013). Endochondral ossification is a very well-characterized
process that takes place in long bones. A cartilage cast
is invaded by mesenchymal progenitors, which leads to
the appearance of a chondrocyte-enriched growth plate that
allows longitudinal bone growth, and an osteoblast-driven
ossification center in each epiphysis. Concurrently, cells in the
periphery of the cartilage cast will differentiate into osteoblasts,
which create the bone cortical structures (Long and Ornitz,
2013).
Once formed, several cells from different origins end up
composing the skeleton. The osteoblast is considered the most
anabolic bone cell, due to its ability to secrete and calcify
the extracellular matrix. Osteoblasts are cuboidal cells that
lie on the surface of bone matrix (Long, 2012). They are
derived from MSCs that can also differentiate into adipocytes,
myoblasts, chondrocytes and fibroblasts (Augello and De Bari,
2010). Differentiation into osteoblasts is a complex process, in
which serial commitment landmarks are achieved sequentially
(Figure 1). It is accepted that during the first steps of
commitment, these progenitors can still express stem markers
and chondrocyte markers (e.g., SOX9). Pre-osteoblasts have
already lost signature genes of the chondrogenic profile, and
they start to express certain specific markers associated with
the osteoblast linage, although they cannot produce extracellular
matrix yet. These osteoblast-specific genes include transcription
factors such as RUNX2, DLX5 and SP7 (Osterix). Soon after,
other markers that are related to matrix formation start to be
expressed: osteocalcin (Bglap2), fibromodulin (Fmod), and bone
sialoprotein (Ibsp), among others (Franceschi et al., 2007; Long,
2012).
Once osteoblasts have reached the bone formation phase,
four outcomes may occur: (1) they get trapped in bone
matrix as osteocytes; (2) they become bone-lining cells; (3)
they enter apoptosis; and (4) they can trans-differentiate into
cells that depose chondroid tissue (Franz-Odendaal et al.,
2006; Rochefort et al., 2010). Typically, osteocytes are closed
in lacunae inside calcified bone. In the beginning of this
embedding process, young osteocytes still look like secretory
cells and express osteoblast markers. Some of these will be
lost during terminal differentiation, while mature osteocytic
markers appear (Rochefort et al., 2010). Osteocytes tend to
express higher levels of FGF23 (fibroblast growth factor 23),
NPY (neuropeptide-Y), RLN (reelin), SOST (sclerostin), DMP1
(dentin matrix acidic phosphoprotein 1), PHEX (phosphate-
regulating neutral endopeptidase, X-linked), PDPN (gp38/E11),
while matrix metalloproteinases and collagen proteins are
more closely related to the osteoblast state (Paic et al.,
2009). Recently, relevant functions have been attributed to
osteocytes, including bone remodeling and regulation of the
hematopoietic stem cell niche (Asada et al., 2013). Remarkably,
osteocytes show dendritic-like cytoplasmic prolongations (50–
60 per cell) that form a canalicular system inside bone
(Rochefort et al., 2010; Klein-Nulend et al., 2013). These
structures serve for sensing and interpreting mechanical
inputs like bone loading (Rochefort et al., 2010; Xu et al.,
2012).
Bone resorption is the process by which the mineral
extracellular matrix is degraded. This process is primarily
carried out by osteoclasts, which are derived from monocytes
and macrophages (Ikeda and Takeshita, 2016). They proliferate
in the bone marrow, and fuse to give rise to multinuclear
reabsorbing cells close to the resorption region. Osteoclast
progenitors express RANK (receptor activator of nuclear factor-
κB), which interacts with RANKL (receptor activator of nuclear
factor-κB ligand). Several cells produce RANKL, including
osteoblasts, osteocytes, stromal cells and lymphocytes (O’Brien
et al., 2013; Ikeda and Takeshita, 2016). The RANK activation
process can be antagonized by osteoprotegerin (OPG), a RANKL
competitor that is mainly expressed by osteoblasts (Simonet
et al., 1997). Other factors contribute to the activation and
function of osteoclasts, such as vitamin D and SOST, which
is also mainly produced by osteocytes (van Bezooijen et al.,
2005).
THE MAPK SIGNALING PATHWAYS
Introduction to the MAPKs
MAPKs are a family of enzymes that are implicated in a series
of processes in which extracellular stimuli (e.g., environmental
stress, growth factors and cytokines) are transduced into different
cellular actions. In some cases, they act as a signaling hub
in which different signaling pathways converge to activate a
MAPK in a given time frame or tissue. Conventional MAPK
members are the extracellular signal-regulated kinases 1/2
(ERK1/2) and ERK5, c-Jun amino (N)-terminal kinases 1/2/3
(JNK1/2/3), and the p38 isoforms (p38α, p38β, p38γ, and
p38δ) (reviewed in Cargnello and Roux, 2011). All of them
contain a Ser/Thr kinase domain, activated by phosphorylation
by other Ser/Thr kinases. Thus, MAPK signaling constitutes
a series of phosphorylations, in which several elements are at
play until the final substrate is targeted. Therefore, once stimuli
have reached the cell, MAPKK kinases (MAP3K) are activated
and phosphorylate MAPK kinases (MAP2K), which in turn
phosphorylate and activate the aforementioned MAPKs. Each
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FIGURE 1 | p38 implication in osteoblast differentiation. Osteoblast differentiation is characterized by the expression of a specific cohort of proteins depicted in
the lower panel. p38 is related both to differentiation and proliferation of bone progenitors. p38-mediated phosphorylation promotes progression in osteogenesis by
the enhancement of the activity or expression of osteoblast-specific transcription factors genes. Direct arrows indicate direct phosphorylation while dashed arrow
indicates indirect action of p38. Phosphorylated residues are specified for every target.
MAPK group has its own series of upstream activators, thus each
represents a specific signaling cascade (Cuadrado and Nebreda,
2010).
JNK Signaling in Osteoblastic
Differentiation
The role of JNK in osteoblastogenesis seems to be somewhat
contradictory, with different functional outputs depending on
the study. For instance, interleukin-1β (IL1β) and tumor
necrosis factor-α (TNFα) favor JNK activation and this effect is
determinant for osteoblast differentiation of human periosteal
cells (Hah et al., 2013). Moreover, Liu et al. found that
inhibition of the JNK route by chemical inhibitors or siRNAs
led to decreased mineralization and downregulation of several
osteogenic markers, while its activation by a constitutive active
form favored osteogenesis. These effects were, at least in part,
due to reduced SMAD6 binding to BMPRI (BMP receptor I),
which allows SMAD1 to access the receptor (Liu et al., 2011).
However, another effect of JNK activation might be to negatively
regulate osteogenesis. JNK1 reduces RUNX2 transcriptional
activity by phosphorylation at Ser104 (Huang et al., 2012). In
addition, the inhibition of JNK with SP600125 in human MSC
increases ALP activity induced by BMP-2 (Biver et al., 2014). This
inhibitory action may also integrate SMAD1 signaling, as MAPK
phosphorylation is necessary for GSK3β (Glycogen synthase
kinase 3β)-induced SMAD1 degradation (Fuentealba et al., 2007;
Biver et al., 2014).
ERK Signaling in Osteoblastic
Differentiation
Both ERK1 and ERK2 are expressed in osteoblasts and have
relevant functions in bone metabolism. There is genetic evidence
of the implication of the ERK pathway in osteogenesis. First,
the expression of a dominant negative form of MEK1 under
the regulation of the osteocalcin promoter (mOG2:Mek1DN)
exhibits calvarial and clavicular defects, which phenocopy the
Runx2 deficiency. The phenotype of Runx2+/− is recovered
by crossing these mutant mice with a constitutive active form
of MEK1 (mOG2:tgMek1SP) (Ge et al., 2007). Matsushita and
collaborators generated the double mutant Erk1−/−;Erk2Prx1:Cre.
They showed the positive effect of ERK1 and ERK2 on osteoblast
differentiation, and the inhibitory effect of these MAPKs on
chondrocyte differentiation at the perichondrium. In addition,
ERK has certain effects on RANKL in these cells, which has an
impact on osteoclast activation (Matsushita et al., 2009).
RUNX2 phosphorylation is the action of ERK signaling
on osteoblast specification that has been most widely studied.
First, use of the MEK1 inhibitor PD98059 blocks osteocalcin
induction by RUNX2 (Xiao et al., 2000). U0126, another MEK1/2
inhibitor, halts the expression of osteocalcin and Ibsp mediated
by BMP7 and ascorbic acid (Xiao et al., 2002a). In addition,
FGFs activates pERK, and subsequently a phosphorylated form
of RUNX2 is detected. Again, these effects can be blocked by
U0126 (Xiao et al., 2002b). Finally, the same group proved the
existence of four serine residues (Ser43, Ser301, Ser319, and
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Ser510) targeted by ERK1/2. Ser301 and Ser319 were found to
be responsible for RUNX2 activating abilities (Ge et al., 2009).
The increase in pRUNX2 transcriptional activity induced by ERK
could be attributed to the binding of cofactors such as CREB,
CBP/p300 or vitamin D receptor (Sierra et al., 2003), as seen in
p38 phosphorylation (Greenblatt et al., 2010). Related to this,
an increase in cytoplasmatic pERK has been associated with
an increment in nuclear RUNX2 upon overexpression of the
transmembrane glycoprotein CD99, which implies that RUNX2
phosphorylation takes place in the cytoplasm (Sciandra et al.,
2014).
NF1 (neurofibromatosis type I) is a GTPase-Activating
Protein that turns off Ras action on ERK signaling. The
inactivating mutation of NF1 seems to have different results
depending on the developmental status at which deletion takes
place (Greenblatt et al., 2013). In fact, analysis of the osteoblast-
specific mutant of Nf1 shows a blunted response to BMP-2 that
is overcome when ERK was inhibited by U0126 (de la Croix
Ndong et al., 2015). Besides differentiation, ERK is related to the
activity of cyclinD1, enhanced by PTH and PTHrP, and favoring
osteoblast proliferation (Datta et al., 2007). Recently, it has been
shown that ERK regulates the antiapoptotic and proliferative
effects of EGF on osteoprogenitors (Chandra et al., 2013).
p38 MAPK Cascade
The p38 MAPK family is composed of four proteins: p38α
(encoded by the geneMapk14), p38β (Mapk11), p38γ (Mapk12),
and p38δ (Mapk13). Their coding genes have a distinct tissue
distribution and they appear differentially expressed, being
Mapk14 the most highly expressed (Cuadrado and Nebreda,
2010). p38 MAPKs are substrates for three MAP2K (MKK6,
MKK3, and MKK4). The contribution of each of these MAP2K
to p38 MAPKs activation depends on the stimulus and the cell
type (Alonso et al., 2000; Brancho et al., 2003; Remy et al.,
2010; Figure 2). The MAP3Ks that lead to p38MAPKs activation
are ASK1, DLK1, TAK1, TAO1, TAO2, TPL2, MLK3, MEKK3,
MEKK4, and ZAK1 (Cuadrado and Nebreda, 2010). p38α can
also be autophosphorylated, due to activation through ZAP70,
p56lck, and TAB1, and downregulation of Cdc47 (Cuadrado and
Nebreda, 2010).
It is known that there are several scaffold complexes along
this route that facilitate MAPK-MAP2K interaction or locally
increase the concentration of effectors of the MAPK cascade,
driving fine spatio-temporal regulation. The most commonly
reported molecules related to this function belong to the protein
family named JIP (from c-Jun NH2-terminal kinase-interacting
protein) that can tether p38 and JNK to their upstream MAP2K.
JLP, which have the isoforms JIP4 and SPAG9 (Kelkar et al.,
2005; Dhanasekaran et al., 2007) and JIP2, have been implicated
in regulating p38 by tethering to MKK3, MEKK3, and MKK4
(Dhanasekaran et al., 2007). The role of these scaffold proteins
in regulating MAP2K action could be of special interest, as it has
been shown that constitutive activation of MKK3 or MEK1 has
deleterious effects on BMP-induced osteoblastogenesis (Huang
et al., 2014). Apart from JIP proteins, there are other potential
MAPK scaffolds: RACK1 (Arimoto et al., 2008), KSR-2 (Liu et al.,
2009), Sec8 (Tanaka et al., 2014) and the osmosensing scaffold
for Rac-MEKK3-MKK3 (OSM) (Dhanasekaran et al., 2007). Out
of these, Mapk8ip2 (JIP2) is detected in the developing skeleton,
and Exoc4 (Sec8 protein), which interacts with JIP4, is expressed
in bone cells (www.genecards.org and www.eurexpress.org).
Besides the aforementioned proteins, TAK1 and TAB1 could
also be considered a sort of scaffold proteins, as they facilitate
the recruitment and activation of upstream effectors of the
p38 pathway. However, no MAPK scaffold proteins have been
investigated in osteoblast development in vivo to date.
p38 MAPKs are inactivated mainly by dephosphorylation by
certain phosphatases belonging to the DUSP family (Bermudez
et al., 2010). Moreover, the catalytic activity of p38α is modulated
according to how many and which threonine or tyrosine
residues are phosphorylated in the activation loop (Zhang et al.,
2008). Like any other relevant molecule, p38 is also regulated
by mechanisms such as acetylation, protein degradation and
stabilizing cofactors and, obviously, changes in the expression of
their coding genes (reviewed in Cuadrado and Nebreda, 2010).
p38α is localized in the nucleus and the cytoplasm (Raingeaud
et al., 1995). Its localization depends on activation and on active
transport, as p38 does not have a nuclear localization signal. It
is known that DNA damage favors phosphorylation and nuclear
accumulation of p38α, probably by releasing p38α from TAB1 or
MK2, as they act as cytoplasmatic anchors (Wood et al., 2009).
p38 AND MESENCHYMAL
DIFFERENTIATION
The p38 pathway has been implicated in the differentiation of
several mesenchymal cells. Most reports on this topic have been
cell-based studies in which activation or inhibition of the pathway
was achieved mainly pharmacologically.
Adipocyte Differentiation
There is some controversy about the role of p38 in adipogenesis.
Some authors claim that it depends on the species or on
the specific cell type used in vitro, where different factors
could be at play. The generation of a tissue-specific knockout
would shed light on this theme. p38 was linked to the
phosphorylation of C/EBPβ and the expression of PPARγ
(peroxisome proliferator-activated receptor-γ) in 3T3-L1 cells
(Engelman et al., 1998). In fact, the overexpression of an active
form of MKK6 favors adipocyte differentiation (Engelman et al.,
1999). (2S)-7,4′-dihydroxy-8-prenylflavan also stimulates the
adipogenic program and glucose uptake via p38 (Ji et al., 2015).
Contrary to the main current of knowledge regarding BMP-
directed osteogenesis, this cytokine also stimulates adipogenesis
of mesenchymal precursors via p38, probably involving SMAD
proteins as well (Hata et al., 2003; Huang et al., 2009). Regarding
adipocyte physiology, one of the few experiments performed
on living animals was the administration of the p38 inhibitor
FR167653. This treatment significantly reduced weight gain,
fat depots and adipocyte size (Maekawa et al., 2010). p38 also
seems relevant for brown adipocyte commitment, as seen with
DUSP10 induction (Choi et al., 2013) or the inhibitory effects
of silica nanoparticles (Son et al., 2015). Indeed, NPY seems to
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FIGURE 2 | p38 triggers involved in osteogenesis. Numerous stimuli, through distinct mechanisms, lead to p38 MAPK phosphorylation. Activated p38
phosphorylates important osteoblast-related transcription factors, which will enhance osteogenic gene expression. pp38 can also trigger other pathways through the
activation of cytoplasmic-acting substrates such as AKT and pMK2. Sharp arrows indicate direct activation. Dashed arrows indicate an unknown or indirect
mechanism of action while the red flat-tipped arrow denotes inhibition.
affect the brown fat gene program and reduce p38 and CREB
phosphorylation (Wan et al., 2015).
Other studies describe contrary effects. For example, p38
activates CHOP, a negative regulator of C/EBPβ (Wang and
Ron, 1996), and also blocks NFATc4, which is a transcription
factor for Pparg (Yang et al., 2002). In chicken adipocytes,
adiponectin prompts a cascade through p38/ATF2 that inhibited
CEBPα, and affects preadipocyte differentiation (Yan et al., 2013).
Adipogenesis conducted by microtubule affinity-regulating
kinase 4 (Marc4) depends on JNK activation and p38
downregulation in 3T3-L1 (Feng et al., 2014). p38 activity seems
to decrease during adipocyte differentiation, and inhibition
of p38 augments PPARγ transactivation and other adipocyte
markers. Furthermore, p38-deficient MEFs have increased
expression of adipogenic markers such as adiponectin or leptin
(Aouadi et al., 2006). Strikingly, the same group proposed a
positive role for p38 during human adipocyte differentiation,
mainly based on C/EBPβ phosphorylation (Aouadi et al., 2007).
Ferguson et al. linked the role of DUSP1 phosphatase to the
deactivation of p38 and ERK during the first steps of preadipocyte
commitment, which establishes a framework for self-regulatory
feedback (Ferguson et al., 2016).
Myoblast Differentiation
p38 MAPK isoforms have multiple roles in muscle development
and homeostasis in the adult. They control self-renewal,
proliferation, asymmetric division and differentiation of satellite
cells (Brien et al., 2013; Bernet et al., 2014). Early studies show
higher p38α, β, and γ levels during myoblast maturation, and
that p38 inhibition blocks muscle-specific gene transcription
(Cuenda and Cohen, 1999; Zetser et al., 1999). p38 activity is
absolutely required for the transition from proliferating satellite
cells into terminally differentiated myoblasts (Puri et al., 2000).
This control of the muscle-specific gene program is performed
through multiple steps that finally lead to activation of key
myogenic transcription factors. For instance, p38 induces the
transcriptional activity of MEF2 family members through direct
phosphorylation at Thr293 (Wu et al., 2000; Lluis et al., 2006).
In addition, p38 also phosphorylates and activates the obligate
MyoD partner E47 (Lluis et al., 2005). Several reports indicate
that p38 activity is required for chromatin remodeling, to allow
access and stabilization of the binding of myogenic transcription
factors to myogenic loci (Lluis et al., 2006). These mechanisms
involve histone acetylation by PCAF and p300, and recruitment
of the SWI/SNF complex (Simone et al., 2004; de la Serna et al.,
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2005). Subsequently, p38 activity is important for myocyte fusion
and myofibrillogenesis (Gardner et al., 2015).
More recently, the role of p38 in muscle development
has been extended to the activation of satellite cells during
muscle regeneration. Muscle regeneration takes place in a highly
inflammatory environment, and inflammatory cytokines such
as IL6 or TNFα activate p38 (Li et al., 2014c). Signaling from
p38α/β is involved in the exit of satellite cells from quiescence
(Jones et al., 2005; Brien et al., 2013), and arranges asymmetric
division and self-renewal (Troy et al., 2012; Bernet et al., 2014).
Importantly, skeletal muscle aging results in a loss of muscle
mass and regenerative capacity. These defects arise because
satellite cells from aged mice fail to self-renew and increase p38
activity. Since pharmacological manipulation of p38α/β activity
ameliorates these age-associated defects, this could be a potential
therapeutic opportunity to treat muscle wasting (Bernet et al.,
2014).
Osteoblast Differentiation
One of the first studies to indicate that p38, ERK, and JNK were
activated during osteoblast differentiation of human MSC was
Jaiswal et al. (2000). Gallea and collaborators showed that ERK
and p38 activation in C2C12 favored osteoblast determination
(Gallea et al., 2001). Soon after, it was shown that the inhibitor
SB203580 impairs MC3T3 pre-osteoblast differentiation and the
expression of osteoblast markers such as ALP, OC, and collagen
(Suzuki et al., 1999, 2002). As will be seen later, many stimuli
have been assayed as triggers of p38 activation in osteoblasts, to
explore their osteogenic activities.
THE STUDY OF p38 IN BONE: DIFFERENT
STRATEGIES, THE SAME GOAL
Knockouts of p38
Different groups have generated germline knockout mice in
which the p38 pathway is mutated. It should be stated that
p38α is the most highly expressed isoform of p38-MAPK in
osteoblasts (Greenblatt et al., 2010; Rodriguez-Carballo et al.,
2014). Embryos with a homozygous deletion of p38a, as well
as embryos with a double knockout of Mkk3/Mkk6, die during
embryogenesis, while mutations of Map2k3 (MKK3), Map2k6
(MKK6), Mapk11, Mapk12, and Mapk13 are viable (Cuadrado
and Nebreda, 2010). Both Map2k3−/− and Map2k6+/− display
severe skeletal defects in long bones, while onlyMap2k3−/− show
abnormalities in craniofacial bone structures (Greenblatt et al.,
2010). The embryonic lethality ofMapk14 loss is associated with
neural and cardiac defects (del Barco Barrantes et al., 2011).
Initially, a lack of Mapk11 was not implicated in severe defects
(Beardmore et al., 2005), although later it has been associated
with some mild bone defects (Greenblatt et al., 2010). The
Mapk13−/− mice has reduced sensitivity to skin carcinogenesis
(Schindler et al., 2009), as well as higher insulin secretion and
tolerance to glucose (Sumara et al., 2009). No bone phenotype
was described in the original article in which Mapk12−/− and
Mapk13−/− were generated (Sabio et al., 2005), or in successive
studies.
In the last 5 years, three studies reported the use of bone
conditional knockouts affecting the p38 pathway in osteoblasts
(reviewed in Thouverey and Caverzasio, 2015a). Greenblatt
and collaborators’ integral approach involved analysing the
deletions of different effectors of the pathway. The conditional
deletion of MAP3K TAK1 in pre-osteoblasts leads to defects
in osteoblast differentiation and bone formation that affects
the entire skeleton. In fact, the phenotype resembles human
cleidocranial dysplasia, which is related to RUNX2 mutations.
Indeed, one of the conclusions of the study is that RUNX2
is a target of p38 kinase activity, which is essential to the
transactivation function of RUNX2 (Greenblatt et al., 2010).
Craniofacial defects are mainly associated with the function
of TAK1, MKK3, and p38α, particularly when it affects pre-
osteoblasts, as with the use of an Osterix-driven recombinase
(Greenblatt et al., 2010; Rodriguez-Carballo et al., 2014). No
cranial phenotype was described when an osteocalcin-Cre animal
model was used (Thouverey and Caverzasio, 2012). Additionally,
with the latter approach, a post-natal bone acquisition defect
starts only after 5 weeks of age and disturbs trabecular and
cortical bone volumes of mice (Thouverey and Caverzasio, 2012).
A doxycycline-induced recombinase can be used to monitor the
impact of p38α deletion in osteochondroprogenitors at different
time points. When the deletion starts at 3 weeks of age, the
anabolic defects are mainly trabecular at 30 weeks of age, and
cortical at 60 weeks. When the deletion starts in young adults
(circa 8 weeks of age), only cortical defects are encountered. This
means that p38α function is particularly important at different
stages of osteoblast commitment throughout life (Rodriguez-
Carballo et al., 2014). Interestingly, this low bone mass model
was also used to hypothesize about the crosstalk between the
skeleton and the adipose tissue (Rodriguez-Carballo et al.,
2015).
Pharmacological Inhibitors of p38
The use of knockout models represents the most faithful, general
analysis of MAPK activity on tissues. Primary osteoblast cultures
from these knockout animals, or the manipulation of pathway
effectors (via constitutive activation or dominant negative forms),
allows molecular analysis in specific models. However, the most
frequent approach is the use of selective inhibitors of the different
MAPKs. The most common p38 inhibitor is the pyridinyl
imidazole molecule SB203580 (Lee et al., 1994; Cuenda et al.,
1995). This is considered a highly selective p38α/β inhibitor
and has been widely used for more than 20 years (it had over
6000 PubMed entries up to 2015). Nevertheless, it has been
shown that it can inhibit other kinases, such as GAK, CK1,
RIP2, RAF, and GSK3, and the formation of ZMP from AICAR
(Bain et al., 2007). The SB203580 inhibitor has been assayed in
some inflammatory skeletal conditions, such as arthritis (Badger
et al., 1996). BIRB0796 is evenmore powerful at blocking p38α/β,
but at moderate doses it can also halt the activity of p38γ,
p38δ, and JNK2α2 (Bain et al., 2007). SD-822 is considered a
more selective p38α inhibitor (Koppelman et al., 2008) and has
been used in studies of osteoarthritis to reduce the outcome of
the disease (Medicherla et al., 2006). Caverzasio and colleagues
showed the potential benefits of this inhibitor for the treatment
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of osteoporosis, as it reduces osteoclast activity (Caverzasio et al.,
2008).
p38 Osteogenic Targets
The osteogenic potential of p38 kinase is related to its capacity to
phosphorylate and increase the activity of some key osteogenic
transcription factors. As explained above, both ERK and
p38 can phosphorylate RUNX2, boosting its transcriptional
potential (Ge et al., 2009, 2012; Greenblatt et al., 2010; Artigas
et al., 2014). In addition, our group has described new p38
phosphorylation targets in recent years. For instance, BMP-
2 stimulus increases DLX5 transactivation of the Sp7 (Osx)
promoter through a feed-forward mechanism. First,Dlx5mRNA
levels are elevated by BMP treatment (Miyama et al., 1999;
Luo et al., 2001; Holleville et al., 2003; Ulsamer et al., 2008;
Rodriguez-Carballo et al., 2011). Then, post-translationally,
DLX5 is phosphorylated by p38 MAPK at serines Ser34 and
Ser217, which facilitates the recruitment of p300 (Ulsamer
et al., 2008; Figure 1). Another DLX member, Dlx3, is also
induced by BMP-2. In this case, it occurs through cooperation
between SMAD5 and pp38 as they translocate to the nucleus
and exert their function on the Dlx3 promoter (Yang et al.,
2014). These p38-activated osteogenic events continue with
the phosphorylation of Osterix at serines Ser77 and Ser33. As
for DLX5, these modifications represent an increase in the
transcriptional ability of OSX by helping to recruit p300 and
BRG-1 (Ortuno et al., 2010, 2013). It was also shown that
OSX can cooperate with RUNX2 to induce Col1a1 (Ortuno
et al., 2013). In fact, soon after, it was proven that indeed OSX
and RUNX2 bind each other and cooperate to increase their
transcriptional power. This interaction requires the action of
p38 and ERK MAPKs, as mutation of the phosphorylation sites
of RUNX2 and OSX prevented their interaction (Artigas et al.,
2014).
In addition to these classic osteogenic targets, p38 can
phosphorylate ATF members at threonines Thr69 and Thr71,
as well as CREB at the serine Ser133. Both ATF and CREB
are transcriptional co-factors and, again, these phosphorylations
increase their transactivation capacity, including the recruitment
of histone acetyltransferase p300 (Livingstone et al., 1995; Waas
et al., 2001). More importantly, ATF4 phosphorylation by RSK2
has been shown to be absolutely required for bone development
(Yang et al., 2004). Both ERK and p38 turn on RSK2 in different
cell types (Siebel et al., 2013; Czaplinska et al., 2014), which then
can lead to activation of ATF4 by its phosphorylation at Ser251
(Yang et al., 2004).
Signaling Interaction between MAPKs in Osteoblasts
Very few studies have focused on the degree of interaction
between different MAPK pathways. The crosstalk between
pathways can be both opposed and cooperative. As a rule of
thumb, inhibition of one MAPK pathway activates the other. The
dominant negative form ofMek (MekDN) favors the activation of
p38, while the constitutively active form has the opposite effects.
The same goes for ERK when Mkk6dn and Mkk6sp are used
(Ge et al., 2012). Nevertheless, blocking of both pathways by
SB203580 and U0126 has deleterious consequences on calvaria
mineralization in organotypic cultures (Ge et al., 2012). Similarly,
some reports showed that osteogenic effects require cooperation
between JNK and p38 signaling (Guicheux et al., 2003).
p38 and Cell Migration
Other actions besides participation in cell proliferation and
differentiation are attributed to p38 MAPK, including control of
cell migration. This function is vital to understand p38 MAPK’s
role in physiological processes, such as chemotaxis, fracture
healing and wound closure, as well as the consideration of
p38 as a target to diminish the invasiveness of cancer cells.
The first model in which p38 was associated with cell motility
was endothelial cells. SB203580 inhibited VEGF-induced cell
migration (Rousseau et al., 1997). Subsequently, p38 was shown
to be essential to cell migration in a plethora of different cell
types. In other studies, p38 is negatively linked to cell motility.
The loss of p38δ has been associated with an increase in cell
motility and proliferation of squamous cancer cells (O’Callaghan
et al., 2013). In C2C12, interleukin-17 inhibits cell migration by
downregulating urokinase through p38α activation (Kocic et al.,
2013).
As said, the positive link between p38 and cell movement
appears evident. In skeletal cells, p38 activation is positively
related to cytoskeletal reorganization and stimulation of cell
motility. In 2004, it was reported that PDGF stimulated the
proliferation andmigration ofMC3T3 through differentMAPKs.
This migration halted when p38 was inhibited, but not when
JNK or ERK were blocked (Mehrotra et al., 2004). The flavonoid
quercetin impairs cell migration in osteoblastic cells, but the
inhibition of ERK and p38 stops this effect (Nam et al., 2008). Our
group studied the function of BMPs as chemotactic agents and
as inductors of actin cytoskeletal reorganization in mesenchymal
cells. These events require the activation of two pathways:
PI3K/CDC42/LIMK1 and p38/MAPKAP2/HSP25. Moreover, in
fibroblasts depleted for Mapk14 or Mapkapk2, BMP-2 signaling
could not favor actin cytoskeletal reorganization and induction
of movement (Gamell et al., 2008, 2011). Another interesting
aspect of p38 in osteoblastic matrix remodeling is attributed to
its role in a model of collagen contraction (Parreno and Hart,
2009).
Fracture assays can be performed in vivo and in vitro.
In a model of fracture healing in rat, TNFα stimulates the
proliferation andmigration of bonemarrowMSCs to the fracture
site. This effect was explained by the activation of p38 and
inhibition of differentiation in this area, as shown in vitro (Zhou
et al., 2006). These migratory effects of TNFα were corroborated
in vitro with MSCs (Fu et al., 2009).
PTH treatment stimulates amphiregulin in osteoblasts. This
osteoblast expression enhances the migration and recruitment
of close-by mesenchymal progenitors, due to signaling on EGFR
through PI3K and p38 (Zhu et al., 2012). SDF-1 (stromal cell-
derived factor-1) is described as an inductor of migration of
umbilical cord MSCs through activation of AKT, ERK and
p38 (Ryu et al., 2010). In fact, shear stress stimulation of JNK
and p38 signaling can also provoke SDF-1 secretion in human
mesenchymal cells, which activates the CXCR4 receptor and
favors migration (Yuan et al., 2012).
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SIGNALING TRIGGERS p38 IN
OSTEOBLAST FUNCTION
The great variety of stimuli that can activate MAPK and
the extended use of specific inhibitors have facilitated the
evaluation of the MAPK role in osteogenesis (Figure 2). These
factors make it easier to design experimental studies to validate
different osteogenic treatments. However, conclusions about
the specific action of a given treatment that is supposed to
affect MAPK signaling should be treated with caution. First,
inhibition of a MAPK could favor the activation of another
MAPK. Secondly, different inhibitors have associated effects that
have not been characterized fully. Third, MAPK pathways are
stress-activated cascades, and if there are no proper controls,
osmotic stress could account for part of the related effects. And
fourth, too often researchers do not ascertain which mechanism
activates p38.
Osteogenic Hormones and Growth Factors
p38 Is a Non-Canonical TGFβ/BMP Signaling
Pathway
The stimulation of p38 by BMP through TAK1 was first observed
in the PC12 cell line (Iwasaki et al., 1999). Then, it was shown
how BMP and TGFβ activate p38, ERK and JNK in different
mesenchymal cells, including osteoblasts. The involvement of
these MAPKs has been observed in different osteogenic in vitro
models (Gallea et al., 2001; Viñals et al., 2002; Guicheux et al.,
2003). A recent report showed that p38 was predicted to account
for 20% of the phospho-residues identified after treatment of
MSCs with BMP (Halcsik et al., 2013). TGF-β provokes the
phosphorylation of p38, ERK and JNK in a very rapid manner
in MC3T3 and primary osteoblasts (Arnott et al., 2008). p38 and
ERK are needed for Col3a1 expression in UMR cells under BMP
or TGF-β treatment (Selvamurugan et al., 2004). In addition,
p38 is necessary for TGF-β-induced synthesis of VEGF in
MC3T3 (Tokuda et al., 2003). Although essentially independent,
there is a certain level of cross-regulation between SMADs and
p38. For example, in human osteoblast cells, inhibition of p38
by SB203580 seems to make SMAD1 phosphorylation and its
nuclear accumulation difficult (Noth et al., 2003). In addition,
both signaling pathways are needed for BMP5 induction of limb
development (Zuzarte-Luís et al., 2004). Nevertheless, p38 and
ERK should be inhibited by BMP4 to guarantee self-renewal and
stemness (Qi et al., 2004).
BMP signal transduction through p38 has been studied in
several cell models. As mentioned previously, the onset of
the cascade begins, as for SMADs, at BMP receptor (BMPR)
level. Both SMADs and p38 need the kinase activities of
BMP receptor complexes. After receptor triggering, MAP3K
TAK1 is activated. Mechanistically, it is well-established that
TGF-b regulates the TAK1/p38 pathway through recruitment
and ubiquitylation of TRAF6 by activated receptor complexes
(Sorrentino et al., 2008; Yamashita et al., 2008; Figure 3). BMPRs
form a complex with NRAGE, TAK1, XIAP, and TAB1, which
favor p38 activation (Yamaguchi et al., 1999; Kendall et al.,
2005). Interestingly, a member of the insulin/Rln family, named
Relaxin, can phosphorylate TAK-1 and cooperate with BMP-2 in
promoting osteogenesis by enhancing the BMP activation of the
p38 signaling pathway (Moon et al., 2014).
Wnt Signaling
The Wnt pathway interacts with p38 at different levels. Wnt
can activate p38 through Disheveled proteins, as the silencing of
Dvl-3 avoids Wnt3a-induced ATF2 phosphorylation (Bikkavilli
et al., 2008). At the same time, p38 can reinforce the Wnt/β-
catenin pathway. In COS-7 and endodermic F9 cells, p38α
inactivates GSK3β by phosphorylating its Ser9, allowing β-
catenin to accumulate. Indeed, blocking the p38 pathway affects
the triggering of Wnt3a downstream events (Bikkavilli et al.,
2008). The activation of both p38 and ERK by Wnt3a, and
its effects on pre-osteoblasts’ commitment without disturbing
proliferation, have also been reported (Caverzasio and Manen,
2007). In dental pulp cells, BMP-2 facilitates Lef1 expression
and β-catenin nuclear accumulation. The authors claimed that
this was due in part to p38, as the inhibitor SB20350 prevented
these effects (Yang et al., 2015b). Very recently, Ehyai reported
that p38-mediated phosphorylation onMEF2 enhances β-catenin
nuclear accumulation (Ehyai et al., 2015). The convergence of
both pathways has also been demonstrated at the level of the
WNT receptor LRP6. In HEK 293, LRP6 phosphorylation by
the MAPKs p38, ERK1/2, and JNK is key for the recruitment
of the multiprotein degradation complex that includes GSK3β
(Cervenka et al., 2011; Figure 4). This reciprocal interaction has
a negative feedback loop. GSK3β inhibits the activation of p38
and JNK by binding the MAP3K MEKK4. It was proposed that
GSK3β could potentially phosphorylate an N-terminal residue of
MEKK4, but this has not been proven yet (Abell et al., 2007).
Another indirect negative loop has been proposed in several
models: the expression of Wnt inhibitor DKK-1 relies on p38
activation, as shown in primary osteoblasts (Kamiya et al., 2010;
Figure 4).
Estrogen Receptors
Estrogen receptor (ER) effects take place through the classic
or genomic pathway, in which ERα and ERβ translocate to
the nucleus to bind specific responsive elements on target
genes. However, faster effects need signaling through PKA, PI3K
and MAPK (Honda et al., 2000; Yamakawa and Arita, 2004).
Accordingly, the ER pathway can activate p38, and reciprocally
p38 can act on ER. p38 is stimulated by β-estradiol in human
dental papilla cells, in which both proliferation and some odonto-
osteogenic markers are enhanced, depending on JNK and p38 (Li
et al., 2014b). The activation of p38 by this molecule takes place
through ERα, but not ERβ (Geraldes et al., 2003; Mori-Abe et al.,
2003). In contrast, in human dental pulp cells, the upregulation
of OPG by estradiol is reported, and SB203580 blocks this effect.
Strikingly, these actions do not seem to take place through the
classic ERα and ERβ receptors, as their chemical agonists do
not trigger downstream effects on OPG (Manokawinchoke et al.,
2016). In MC3T3, saponin diosgenin acts on ER and, as a result,
stimulates the production of VEGF via the interplay of p38,
PI3K, and HIF (Yen et al., 2005). In MG-63 osteoblastic cells,
β-estradiol and mechanical stress can phosphorylate ERK and
p38 independently, with different kinetics. By combining both
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FIGURE 3 | Non-canonical BMP/TGFβ signaling. p38 activity can be triggered by a BMP-dependent mechanism. Once BMP receptors (BMPR) are stimulated
they form a complex formed by NRAGE, XIAP, and TAB1, which is responsible of TAK1 activation. Relaxin can act on TAK1, cooperating on p38 activation. Although
considered to be independent from SMAD activity, some cross-regulation have also been reported.
treatments, the researchers reported the synergistic expression of
Ptgs2 (encoding COX2) and Fos by elevating Integrin-b1 levels
(Yeh et al., 2010).
PTH
The first link of PTH with p38 in MC3T3 implicated the
necessary activation of the cAMP-PKA pathway (Rey et al.,
2007). The chronic or intermittent treatment of PTH on the
beta-arrestin-2 (Arrb2) knockout show that the main signaling
pathways implicated are p38 and NFκB (Bianchi and Ferrari,
2009). On the Mkp1 knockout, the interplay between this
phosphatase, p38 and PTH was investigated. The continuous
treatment of PTH leads to effects on p38 signaling by acting
on the phosphatase MKP-1, negatively regulating ERK and
p38 (Mahalingam et al., 2013). PTH downregulates the cell
cycle and apoptosis regulatory protein 1 (CARP1) via p38 in
osteoblastic cells (Sharma et al., 2013). p38 was also needed for
COX2 stimulation by PTH in primary osteoblasts (Park et al.,
2007).
The most relevant study on intermittent treatment with PTH
and the role of p38 has been published recently. As shown
with the conditional knockout Ocn-Cre; p38af /f , PTH could not
exert its anabolic effects in vivo, due to a lack of p38 in mature
osteoblasts. Although the authors reported that, in these animals,
PTH-induced expression of Rankl is supressed, still the net effect
of p38 deletion is reduced ossification, due to the inability of PTH
to induce osteogenic genes. In addition, the authors establish the
possibility that PTH activates p38 through cAMP/PKA signaling
(Thouverey and Caverzasio, 2015b). Mechanistically, it has been
proposed that PTH increases both SMAD and p38 BMP signaling
in MSCs (Yu et al., 2012).
FGF, IGF-1, and VEGF
The first hints of p38 activation by FGF2 in MC3T3 were
reported in 1997, on behalf of MMP1 expression, even before
any commercial pp38 antibody was available (Newberry et al.,
1997). Subsequently, it was proven that FGF2 induces p38
phosphorylation in MC3T3 (Kozawa et al., 1999), and in
immortalized human neonatal calvarial cells (Debiais et al.,
2001). In another report, it was suggested that strontium
ranelate plays a similar role in combination with FGF2.
Moreover, MAPK induction is blocked by an FGF inhibitor
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FIGURE 4 | Role of p38 MAPK in Wnt signaling. Wnt pathway activation leads to β-catenin accumulation, which enables β-catenin to translocate and initiate the
transcription of target genes. p38 participates in the regulation of β-catenin accumulation by targeting different steps of the Wnt signaling. Wnt can activate p38
through Disheveled (Dvl) proteins and at the same time also inactivate GSK3β allowing β-catenin to accumulate. Activated p38 can reinforce GSK3β inhibition
therefore increasing cytoplasmic β-catenin. Moreover, effects of p38 phosphorylation on MEF2 also enhance β-catenin nuclear accumulation. p38 also exerts negative
effects on Wnt signaling since DKK-1 expression (a Wnt inhibitor) relies on p38 activation.
(Caverzasio and Thouverey, 2011). It should be noted
that strontium ranelate alone stimulates p38 and ERK
activation in C3H10T2, inducing proliferation (Caverzasio,
2008). In human MSC, IGF-1 activates p38, JNK, and ERK.
These kinases are essential to the upregulation of Osterix
upon IGF-1 treatment, as this is blocked by chemical
inhibitors (Celil and Campbell, 2005). Although VEGF
cannot activate p38 alone in human adipose mesenchymal
stem cells, it can cooperate with BMP6 signaling to direct
differentiation toward osteoblastic commitment, and to avoid
adipogenesis. This positive collaboration is mediated via
simultaneous activation of p38 and AKT inhibition (Li et al.,
2015a).
AMPK/Adiponectin
Adiponectin can activate p38 and JNK by binding to its
own receptor, as AdipoR1 siRNAs block p38 phosphorylation
in primary trabecular osteoblasts. Interestingly, the p38 and
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JNK cascades are independently and respectively associated
with osteoblast activity and proliferation (Luo et al., 2005).
Indeed, in C3H10/T2 cells, adiponectin induces osteogenic genes
such as Spp1, Bglap, and Ptgs2 via p38 through AdipoR1,
but not AdipoR2. Also, adiponectin favors RUNX2 and CREB
recruitment to Bglap and Spp1 promoters. (Lee et al., 2009).
Adiponectin is also seen as a p38 stimulus to favor RANKL
transcription and at the same time inhibit OPG, thus leading to
osteoclast activation (Luo et al., 2006). Intriguingly, regarding
osteoblastogenesis, the relationship between adiponectin and p38
stimulation may generate different outputs depending on the cell
type. In calcifying vascular smoothmuscle cells, adiponectin p38-
activation is related to impairment of osteoblastic differentiation
(Luo et al., 2009).
Inflammatory Cytokines
Interleukins
Interleukin-1β (IL-1β) activates p38 in MG-63 and MC3T3 cells,
which helps to induce IL-6 and stabilize its mRNA (Kumar et al.,
2001; Patil et al., 2004). In addition, IL-1β activates both ERK
and p38, but not JNK, in MG-63 cells (Lambert et al., 2007). It
also accelerates osteoblastic differentiation, presumably through
p38 activation, as the inhibitor SB2035820 supresses primary
rat osteoblasts’ mineralization (Lin et al., 2011). Conversely,
one report analyzed the negative impact of IL-1β on BMP-
2 osteogenesis. These effects are, at least in part, due to p38
activation by this interleukin (Huang et al., 2014). Moreover, p38
and ERK are linked to IL-1β-induced Opg expression, therefore
presumably preventing resorption (Lambert et al., 2007).
Prostaglandins
In calvarial osteoblasts, PGE2 activates p38 via EP2 and cAMP,
while ERK is triggered via EP4/PKC, and JNK can be activated
by both EP2 and EP4. Inactivation of each pathway results
in decreased osteogenic markers (Minamizaki et al., 2009). In
MC3T3, PGE1 signaling through p38 and ERK increases VEGF
synthesis andALP activity.Moreover, the same authors suggested
that in this cascade, p38 would be downstream of cAMP and
PKA (Tokuda et al., 2001; Kakita et al., 2004). In the cell
line MG-63, 15d-PGJ2 (15-deoxy-delta-12,14-prostaglandin J2)
independently activates p38 in a very rapid manner. The use of
inhibitors PD169316 and PD098580 blocks 15d-PGJ2-induced
PTGS2 transcription (Kitz et al., 2011). The same prostaglandin
prevents cell death of this osteosarcoma line. The mechanism
of action includes signaling via the p38/AKT/Egr-1 axis (Koyani
et al., 2016).
TNFα
TNFα is recognized as an inductor of p38 and is implicated
in IL6 synthesis in MSCs (Zhou et al., 2006) and in MC3T3
(Dai et al., 2006). Huang et al showed that TNFα inhibited
BMP2 osteogenesis via p38. Chemical inhibition of p38 restores
the expression levels of RUNX2 and other osteogenic markers
triggered by BMP-2, despite the presence of TNFα (Huang et al.,
2014). TNFα-mediated p38 activation has also been linked to
Rankl early expression, but not during the late phase (Dai et al.,
2006).
ECM and Adhesion
Rho-Kinase
Endothelin-1 and prostaglandin-F2α (PGF2α) can activate IL-
6 by acting both on Rho-kinase and p38 on MC3T3. The
effects disappear after treatment with the Rho inhibitors fasudil
or Y27632, or the p38 inhibitors SB2035820 and BIRB0796
(Minamitani et al., 2008). Thrombin can also directly activate
ERK and JNK, and indirectly activate p38 through Rho-kinase.
The actions on ERK and p38 lead to an increase of IL-
6 that can be stopped by fasudil and Y27632 (Kato et al.,
2011). Fluid flow forces can also activate PI3K, ERK, and p38
via RhoA-ROCK in osteoblasts (Hamamura et al., 2012). Dr.
Glimcher’s group found that FGD1 signals through CDC42 to the
MAP3K MLK3, which in turn activates p38 and ERK, provoking
RUNX2 phosphorylation. Mutations in FGD1 are associated with
faciogenital dysplasia (FGDY), which is characterized by skeletal
defects that are comparable to the phenotype of Mlk3−/− mice
(Zou et al., 2011).
Extracellular Matrix Proteins
The extracellular matrix holds a set of molecules that can directly
activate the MAPK or are needed for MAPK function. For
instance, calcium, one of the main constituents of bone ECM,
elevates MC3T3 proliferation via ERK and p38 activation, as its
chemical blockage interrupts the proliferative effect (Yamaguchi
et al., 2000). CCNs are ECM proteins that can act as growth
factors and are critical for osteoblast function. CCN-1 to -
6 have a positive impact on Runx2, Sp7, Col1a1, Alp, and
Bglap expression, partly due to activation of ERK and p38
(Kawaki et al., 2011). The expression of BMP4 induced by
CCN3 depends on p38 and JNK function, as demonstrated
with a chemical antagonist and dominant negative MAPK forms
(Tan et al., 2012). Dentin matrix protein1 (DMP1) has been
proven to serve as an inductor of differentiation for odontoblasts
and osteoblasts. It was demonstrated that DMP-1 increases
intracellular calcium levels in several osteoblastic cells, and
stimulates phosphorylation and nuclear translocation of p38,
which leads to activation of downstream targets such as MK2
and HSP27, and nuclear translocation of RUNX2 (Eapen et al.,
2010). DDR2 (Discoidin Domain Receptor-2) is a tyrosine-kinase
receptor with collagen affinity.Ddr2 is transcriptionally activated
by ATF4 and C/EBPβ, where the former is a known target of
p38. At the same time, DDR2 needs p38 activity to trigger Runx2
and osteocalcin expression (Lin et al., 2010). In addition, Plexins
(Plxn) are semaphorin receptors that were originally involved in
cell adhesion and migration. PlxnA2 is expressed in bone, and
its siRNA inhibition reduces phosphorylated levels of SMAD1,
AKT, and p38, as well as Runx2 expression and mineralization.
Moreover, it seems that PlxnA2 activity may be associated with
binding to BMPRs (Oh et al., 2012).
Stresses and Physical Inputs
Chemical Stressors
MAPKs have been traditionally described as stress kinases that
can be triggered bymultiple stressors. The use of certain chemical
compounds was recurrent inmany early in vitro experiments. For
example, arsenate induces p38, and this leads to an increment
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in peroxiredoxin I protein levels in MC3T3, but does not affect
its mRNA levels (Li et al., 2002). Another chemical stressor,
cadmium, requires p38 function to induce PGE2 in primary
osteoblasts (Miyahara et al., 2004). In addition, temperature
stress can also trigger p38 in MSC, which has a positive effect
on their osteogenic commitment. Indeed, chemical blockage of
this MAPK prevents the stimulation of proteins such as RUNX2,
OPN, BSP, and collagen I (Nie et al., 2015).
Hypoxia
In MSCs, hypoxia clearly induces osteoblastic differentiation
through ERK and p38 activation, particularly when they are
seeded in bone-derived scaffolds (Zhou et al., 2013). Similar
effects are seen in periodontal ligament cells when co-cultured
with endothelial cells (Wu et al., 2013). Hypoxia has also been
studied in osteoarthritic osteoblasts, where it upregulates leptin,
which also involves p38 signaling (Bouvard et al., 2014).
Mechanical Inputs
Mechanical loading constantly shapes the skeleton, and some
physical stimuli have been shown to activate p38 in several in
vitro and in vivo experimental settings. Static stretching is an in
vitromodel that tries to reproduce the effects of bone distraction
on osteoblasts. In this model, p38 and ERK are phosphorylated,
which stimulates VEGF release in human MSCs. When these
MAPKs are inhibited, VEGF is no longer activated (Kim et al.,
2010). Using the same model, other authors showed effects of
p38 on BMP-2 and BMP4 production, which in turn activate
Col1a1, Runx2, Spp1, Alp, and Bglap in MC3T3 (Wang et al.,
2012; Zhang et al., 2013). Interestingly, siRNAs against TAK1
dramatically soften this stretching activation in MC3T3, as well
as IL-6 expression, which is also decreased by blocking p38
(Fukuno et al., 2011). ROS17/2.8 cells subjected to stretching or to
microgravity show that inhibition of p38 by SB203580 extended
the time expression of Egr1 (Granet et al., 2001). Physiologically,
stretching forces also play a role in the periodontal space. Indeed,
several reports show that cyclic tension activatesMAPK signaling
and increases osteogenesis in human periodontal ligament cell
(Li et al., 2014a; Suzuki et al., 2014). In this model, p38 and
ERK activation, but not JNK, are related to PTGS2 and BMP2
transcription (Suzuki et al., 2014).
Furthermore, fluid flow shear stress can also activate p38
and ERK in bone marrow stromal cells (Kreke et al., 2008) and
in MG63 (Lee et al., 2008a). The activation of these MAPKs
is associated with the interplay between integrins avβ3 and β1
with the adaptor protein Shc. This leads to Fos, Ptgs2, and Spp1
expression (Lee et al., 2008a). Integrins can also activate p38
by contacting other molecules. In human osteosarcoma cells,
angiopoietin-like protein 2 (ANGPTL2) appears to interact with
integrin α5β1 to promote p38 activation and MMP9 expression,
which favors invasiveness (Odagiri et al., 2014). Fluid flow cell
stress in MC3T3 activates ERK and p38 via Rho kinase, leading
to expression of Ptgs2, Spp1, and Per2 (Hamamura et al., 2012).
Ultrasound, Electric and Magnetic Fields and Lasers
Other osteogenic stimuli that are not related to loading
mechanical forces but electromagnetic waves also have
osteogenic potential via p38 (Xiao et al., 2009). Ultrasounds
can stimulate MAPKs in primary osteoblasts cultures and
favor the expression of metalloproteinase 13 (MMP13), which
increases the binding of Fos and Jun to AP-1 elements at
promoter level. These effects are supressed by treatment with
p38 inhibitors SB2035820 or JNK inhibitor SP600125, but not
when ERK is inhibited (Chiu et al., 2008). Previously, it was
shown that p38 inhibitor SB203580 prevents ultrasound-induced
COX2 and osteocalcin expression in murine cells ST2 (Naruse
et al., 2003). Electromagnetic stimulation increases p38, JNK,
and ERK phosphorylation levels in MC3T3. Inhibition of
these MAPK is related to a reduction in electromagnetically
induced osteopontin, PDGF and VEGF levels (Yumoto et al.,
2015). Similarly, low frequency electromagnetic fields favor
collagen accumulation, probably via p38, as the use of SB203580
diminishes this effect (Soda et al., 2008). In addition, high
frequency fields raise p38 mRNA levels in C3H10T2 (Teven
et al., 2012). Biphasic electric current has also been applied in
an in vitro osteogenic model with human stromal cells. This
stimulus activates both ERK and p38 MAPK pathways, leading
to increased proliferation and induction of VEGF and HIF-α,
which can be supressed by chemical inhibition (Kim et al., 2009).
Pharmacological Compounds
Bisphosphonates were found to induce ERK and p38 pathways,
halt proliferation, and favor apoptosis in sarcoma cell lines
(Kubo et al., 2008). Statins, therapeutic drugs to fight
hypercholesterolemia, can have a positive effect on bone
formation. Simvastatin induces HSP27 specifically via p38
signaling in MC3T3, and SB203580 blocks this effect (Wang
et al., 2003). Generally, statins and bisphosphonates can have a
dual action on bone cells: they can inhibit the ERK pathway, and
accentuate p38 signaling. ERK and p38 seem to be reciprocally
inhibited. The activation of p38 favors OPG overexpression,
while the inhibition of ERK downregulates CD-1, RANKL,
and MCSF. Thus, the net result of bisphosphonate and statin
treatment would be inhibition of osteoblast-induced osteoclast
maturation (Tsubaki et al., 2012). Thiazolidinediones (TZD), a
drug for diabetes type 2 treatment, can also stimulate ERK and
p38 via GPR40 and Ras activation. Apparently, this pathway,
which is independent of PPARγ activity, leads to TZD-induced
osteocyte apoptosis (Mieczkowska et al., 2012).
In traditional Asian medicine, a myriad of herb and
plant compounds have been used historically to treat bone
diseases such as osteoporosis or fractures. Many of these
compounds contain remarkable doses of pro-estrogenic
chemicals, antioxidants or anti-inflammatory agents, and have
been linked to p38 function. Phytoestrogens (isoflavonoids)
group non-steroidal compounds of plant origin that resemble
human estrogens. Some of them have been studied as bone
anabolic therapies, as they increment the levels of several
osteogenic markers. They include genistein (which involve a
p38-RUNX2), 8-prenylkaempferol, sesamin and caffeic acid
3,4-dihydroxy-phenethyl ester (CADPE) (Chiou et al., 2011;
Wanachewin et al., 2012; Liao et al., 2014; Schilling et al.,
2014). Another important group of natural substances is the
flavonoid family. Flavonoids are present in fruit, vegetables and
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seeds, and have long been known for their beneficial effects.
Naringin, ugonin K, neobavaisoflavone, puerarin, quercetin,
icariin and apigenin have shown anabolic abilities in some
osteogenic models both in vivo and in vitro (Ming et al., 2013;
Welch and Hardcastle, 2014; Li et al., 2015b; Zhang et al.,
2015; An et al., 2016). The saponins family also has proven in
vitro osteogenic actions that affect both osteoblast proliferation
and differentiation (Jeong et al., 2010; Niu et al., 2011; Zhou
et al., 2015) and osteoclast activation (Zhou et al., 2015). Other
substances, such as coumarinic compounds, have only been
associated with osteoblast commitment (Tang et al., 2008).
Lactone derivatives affect both p38 and ERK pathways and are
linked to osteoblast function (Lee and Choi, 2011) and osteoclast
impairment (Zhai et al., 2014). Isoquinolines, quinones and
lignans can increase ALP activity and Bmp2 expression, as
well as upstream effectors like RUNX2, in pre-osteoblasts and
mesenchymal cells and in vivo models (Lee et al., 2008b; Kim
et al., 2014; Moon et al., 2015; Yang et al., 2015a). In addition,
phenolic compounds are associated with positive effects on
osteogenesis. A diet enriched in blueberries seems to ameliorate
bone marker levels and diminish bone resorption in rats. These
changes are related to p38 activation and high levels of beta-
catenin (Chen et al., 2010). Xanthonoids in gambogic acid are
linked to decreased osteoclastogenesis and bone loss (Ma et al.,
2015).
CONCLUDING REMARKS
p38 MAPK plays a pivotal role in different steps of osteoblast
differentiation. In vivo, p38 deletion hampers osteoblast terminal
differentiation and the appearance of osteocytes, which directly
affects bone composition and maintenance. Taking into account
the growing number of triggers of p38 activity and the key action
of MAPK in bone development and homeostasis, we should
consider p38 as a central hub for signaling convergence toward
osteoblastogenesis. As seen inmultiple in vitro cell-basedmodels,
p38 integrates inputs from different stimuli. The latter range
from mechanical loading to signaling molecules like cytokines,
of which BMP/TGFβ and Wnt pathways have been the most
widely studied. The in vivo evidence reinforces this hypothesis.
As seen in specific knockouts, deleting some key effectors of the
p38-MAPK pathway affects osteoblast development at different
moments during differentiation. Therefore, disturbing p38 affects
a necessary integrator of various signaling inputs.
Matrix deposition and shaping is a local, fine-tuned event
affected by multiple factors. We know that MAPKs such as p38,
ERK, and JNK are rapidly activated, and are thus convenient
for an anabolic cell like the osteoblast to respond to different
local spurs. Bearing all this in mind, the p38 cascade could
be a good target for anabolic bone therapies. However, the
large number of activators and the different levels of self-
and cross-regulation make it difficult to specifically target it
therapeutically. On another front, assessing p38 activity could
inform clinicians about the ability of bone to respond to anabolic
therapies.
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